ANI Pharmaceuticals Inc. (ANIP)
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANIP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.56B
- P/E (TTM)
- 13.90
- Forward P/E
- 6.72
- EPS (TTM)
- $4.93
- Dividend yield
- None
- 52-week range
- 67.14 – 87.76
- Day range
- 68.28 – 70.20
- Volume / Avg
- 227.26K / 420.66K
- Beta
- —
- Shares outstanding
- 22.72M
52-week range
ANIP stock today
ANI Pharmaceuticals (ANIP) closed at $68.55 on Nov 20, down 0.84% (-$0.58), versus the S&P 500's 3.70% decline. At this level, ANIP sits near the bottom of its 52-week range of $67.14 to $87.76: 21.9% below the high, set on May 8, 2026 and 2.1% above the low. ANIP is down 13.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 14.0%.
ANI Pharmaceuticals trades at 13.9x its trailing twelve-month earnings per share of $4.93. Its forward P/E of 6.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About ANI Pharmaceuticals
Company profileANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nikhil Lalwani
- Headquarters
- Princeton, NJ
- Employees
- 970
- Website
- anipharmaceuticals.com
Financial highlights
Full financialsIn fiscal 2025, ANI Pharmaceuticals generated $883.4 million in revenue, up 43.8% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $78.3 million, for a net margin of 8.9% versus a median of -10.8% in the prior 5 years. Gross margin was 61.4% (up from 59.3%) and operating margin 12.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M |
| Growth | +43.78% | +26.20% | +53.87% | +46.38% | +3.67% |
| Net income | $78.34M | $-18.52M | $18.78M | $-47.90M | $-42.60M |
| EPS (diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$103.38+50.81%
- Strong buy 3
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.51 vs $1.80
- Surprise
- -16.11%
ANIP news
All ANIP news- ANI Pharmaceuticals to Present at Upcoming December Investor ConferenceGlobeNewswire
- ANI Pharmaceuticals, Inc. Details Offer to Acquire Egetis Therapeutics for SEK 5.6BNasdaq
- ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesNasdaqANIP, TWST
- ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha
- ANI Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessGlobeNewswire
- ANI Offers $560 Mln To Acquire Egetis, Expand Rare Disease BusinessNasdaqANIP, WSO.B
- ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessGlobeNewswire
ANI Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZBIOZenas BioPharma Inc. | 23.85 | -4.75% | $1.62B | vs ANIP |
| PGENPrecigen Inc. | 4.21 | +1.20% | $1.51B | vs ANIP |
| AGIOAgios Pharmaceuticals Inc. | 27.60 | -4.03% | $1.65B | vs ANIP |
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs ANIP |
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs ANIP |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs ANIP |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs ANIP |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs ANIP |
Indexes, lists and sector
ANI Pharmaceuticals stock FAQ
What is ANI Pharmaceuticals's stock price today?
ANIP last traded at $68.55 as of Nov 20, 4:00 PM EST, down 0.84% on the day. Prices are delayed at least 15 minutes.
Does ANI Pharmaceuticals pay a dividend?
No. ANI Pharmaceuticals does not currently pay a regular cash dividend.
What is ANIP's P/E ratio?
ANIP trades at a trailing P/E ratio of 13.90 and a forward P/E of 6.72.
Who is ANI Pharmaceuticals's CEO?
Mr. Nikhil Lalwani is the chief executive officer of ANI Pharmaceuticals Inc., which has about 970 employees.
Has ANIP ever split its stock?
Yes. The most recent ANIP stock split was a 1-for-6 split on Jul 18, 2013, one of 3 splits on record.
What is the ANIP 52-week high?
The 52-week high for ANIP is $87.76 and the 52-week low is $67.14. The stock is currently 21.9% below its high.